264 related articles for article (PubMed ID: 19154443)
1. Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.
Cortijo J; Iranzo A; Milara X; Mata M; Cerdá-Nicolás M; Ruiz-Saurí A; Tenor H; Hatzelmann A; Morcillo EJ
Br J Pharmacol; 2009 Feb; 156(3):534-44. PubMed ID: 19154443
[TBL] [Abstract][Full Text] [Related]
2. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
3. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.
Izikki M; Raffestin B; Klar J; Hatzelmann A; Marx D; Tenor H; Zadigue P; Adnot S; Eddahibi S
J Pharmacol Exp Ther; 2009 Jul; 330(1):54-62. PubMed ID: 19386793
[TBL] [Abstract][Full Text] [Related]
4. Roflumilast, a phosphodiesterase-4 inhibitor, improves hyperoxia-induced lung injury via anti-inflammation.
Cao HY; Yu TH; Han CH; Liu WW; Zhang PX; Tang P
Undersea Hyperb Med; 2020; 47(2):189-196. PubMed ID: 32574434
[TBL] [Abstract][Full Text] [Related]
5. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast Prevents the Metabolic Effects of Bleomycin-Induced Fibrosis in a Murine Model.
Milara J; Morcillo E; Monleon D; Tenor H; Cortijo J
PLoS One; 2015; 10(7):e0133453. PubMed ID: 26192616
[TBL] [Abstract][Full Text] [Related]
7. Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice.
Udalov S; Dumitrascu R; Pullamsetti SS; Al-tamari HM; Weissmann N; Ghofrani HA; Guenther A; Voswinckel R; Seeger W; Grimminger F; Schermuly RT
BMC Pulm Med; 2010 May; 10():26. PubMed ID: 20444277
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke.
Martorana PA; Beume R; Lucattelli M; Wollin L; Lungarella G
Am J Respir Crit Care Med; 2005 Oct; 172(7):848-53. PubMed ID: 15961691
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: Modulation of cAMP/CREB/TLR4 inflammatory and fibrogenic pathways.
Essam RM; Ahmed LA; Abdelsalam RM; El-Khatib AS
Life Sci; 2019 Apr; 222():245-254. PubMed ID: 30858122
[TBL] [Abstract][Full Text] [Related]
10. Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury.
Kosutova P; Mikolka P; Kolomaznik M; Balentova S; Adamkov M; Calkovska A; Mokra D
Physiol Res; 2018 Dec; 67(Suppl 4):S645-S654. PubMed ID: 30607971
[TBL] [Abstract][Full Text] [Related]
11. A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro.
Sabatini F; Petecchia L; Boero S; Silvestri M; Klar J; Tenor H; Beume R; Hatzelmann A; Rossi GA
Pulm Pharmacol Ther; 2010 Aug; 23(4):283-91. PubMed ID: 20226872
[TBL] [Abstract][Full Text] [Related]
12. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
13. Roflumilast Ameliorates Airway Hyperresponsiveness Caused by Diet-Induced Obesity in a Murine Model.
Park HJ; Lee JH; Park YH; Han H; Sim da W; Park KH; Park JW
Am J Respir Cell Mol Biol; 2016 Jul; 55(1):82-91. PubMed ID: 26756251
[TBL] [Abstract][Full Text] [Related]
14. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis.
Kim JW; Rhee CK; Kim TJ; Kim YH; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim KH; Kim YK
Clin Exp Pharmacol Physiol; 2010 Nov; 37(11):1055-63. PubMed ID: 20659133
[TBL] [Abstract][Full Text] [Related]
15. Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.
Tannheimer SL; Wright CD; Salmon M
Respir Res; 2012 Mar; 13(1):28. PubMed ID: 22452977
[TBL] [Abstract][Full Text] [Related]
16. Influence of roflumilast on sepsis mice through the JAK/STAT signaling pathway.
Chang X; Hu LF; Ma XJ; Yin J; Liu XY; Li JB
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1335-1341. PubMed ID: 30779101
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
18. LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.
Seehase S; Lauenstein HD; Schlumbohm C; Switalla S; Neuhaus V; Förster C; Fieguth HG; Pfennig O; Fuchs E; Kaup FJ; Bleyer M; Hohlfeld JM; Braun A; Sewald K; Knauf S
PLoS One; 2012; 7(8):e43709. PubMed ID: 22952743
[TBL] [Abstract][Full Text] [Related]
19. 16,16-Dimethyl prostaglandin E2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis.
Failla M; Genovese T; Mazzon E; Fruciano M; Fagone E; Gili E; Barera A; La Rosa C; Conte E; Crimi N; Cuzzocrea S; Vancheri C
Am J Respir Cell Mol Biol; 2009 Jul; 41(1):50-8. PubMed ID: 19059888
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice.
Kim KY; Kim YA; Joo HS; Kim JW
In Vivo; 2024; 38(3):1127-1132. PubMed ID: 38688656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
